SOS1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our observations in this experimental system showed that SOS1 genetic ablation causes a specific suppression of CML development in this mouse model, thus validating the consideration of SOS GEFs as new potential therapeutic targets for this disease that may be particularly useful in those cases where resistance to traditional TKI treatment arises.